SCHEMBL6708280

SCHEMBL6708280

CCOC(=O)C(=CNc1ccc(OC)cc1)C(=O)c1cc(CN2CCOCC2)ccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.48
EPAS1 Q99814 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
TSHR P16473 2/20 0.44
RAB9A P51151 4/20 0.43
LMNA P02545 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MAPK1 P28482 1/20 0.43
STAT3 P40763 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
NPC1 O15118 3/20 0.43
TP53 P04637 2/20 0.43
MEN1 O00255 1/20 0.42
GALR3 O60755 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6708277 1.00 HIF1A (0.48) HIF1AEPAS1SMN1; SMN2MAPTKMT2A
SCHEMBL6709470 0.91 SMN1; SMN2 (0.46) SMN1; SMN2MAPTKMT2ATSHRRAB9A
SCHEMBL6710843 0.91 SMN1; SMN2 (0.46) SMN1; SMN2MAPTKMT2ATSHRRAB9A
SCHEMBL6710700 0.91 SMN1; SMN2 (0.52) SMN1; SMN2MAPTKMT2ARAB9ALMNA
SCHEMBL6710699 0.91 SMN1; SMN2 (0.52) SMN1; SMN2MAPTKMT2ARAB9ALMNA
SCHEMBL6709485 0.91 NPSR1 (0.47) SMN1; SMN2MAPTKMT2ATSHRRAB9A
SCHEMBL6709489 0.91 NPSR1 (0.47) SMN1; SMN2MAPTKMT2ATSHRRAB9A
SCHEMBL6709488 0.91 ALDH1A1 (0.46) SMN1; SMN2MAPTTSHRRAB9ALMNA
SCHEMBL6709484 0.91 ALDH1A1 (0.46) SMN1; SMN2MAPTTSHRRAB9ALMNA
SCHEMBL6711016 0.91 LMNA (0.48) HIF1AEPAS1SMN1; SMN2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents SCHNUTE MARK E (US) 2004-02-05 US disclosed
US-6653307-B2 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors PHARMACIA & UPJOHN COMPANY 2003-11-25 US disclosed
EP-1292575-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-19 EP disclosed
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2001098275-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, IRF3 HIF1A 348/4885EPAS1 947/4885SMN1; SMN2 4052/4885
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, ZC3HAV1L HIF1A 249/4885EPAS1 964/4885SMN1; SMN2 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.